 Shares of DarioHealth NASDAQ:DRIO moved higher by 2 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 423.08 year over year to 0.68, which beat the estimate of 1.40.Revenue of 1,787,000 up by 8.24 from the same period last year, which beat the estimate of 1,550,000.Outlook DarioHealth hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Details Of The Call Date: Aug 12, 2020View more earnings on DRIOTime: 09:00 AMET Webcast URL: 52-week high: 18.8452-week low: 0.20Price action over last quarter: Up 123.19Company Profile DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The companys product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.See more from Benzinga Earnings Scheduled For August 12, 2020 Stocks That Hit 52-Week Highs On Wednesday Stocks That Hit 52-Week Highs On FridayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 